CanSino Biologics Announces Clinical Trial Approval for PCV24 Vaccine in China
CanSino Biologics Inc. (Stock Code:06185.HK) issued a voluntary announcement stating that its 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24) has received approval from the China National Medical Products Administration to conduct relevant clinical trials.
PCV24 utilizes polysaccharide antigens covalently conjugated with protein carriers and a dual-carrier technology, covering the major prevalent pneumococcal serotypes. It is intended for vaccination in individuals aged 2 months (minimum 6 weeks) and above to prevent infectious diseases caused by 24 pneumococcal serotypes. The company has completed the development and validation of purification processes for 24 serotypes of polysaccharides, polysaccharide-protein conjugate bulk production processes, and the final formulation of the product.
CanSino Biologics stated that, as of the announcement date, no 24-valent pneumococcal polysaccharide conjugate vaccine is available on the market either domestically or internationally. The company reminds shareholders and potential investors to exercise caution when trading its shares.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
